Pyramax H-W-2319

Name of the medicinal productPyramax
Opinion holderShin Poong Pharmaceutical Co., Ltd.
748-31 Yoksam-Dong
Gangnam-Gu
Seoul 135-925
Korea
Active substancepyronaridine / artesunate
International non-proprietary name or common namepyronaridine / artesunate
Pharmaco-therapeutic groupAntimalarial
ATC codeP01BF06
Therapeutic indication

For tablets and granules combined:

Pyramax tablets are indicated in the treatment of acute, uncomplicated malaria infection caused by Plasmodium falciparum or by Plasmodium vivax in adults and children weighing 20 kg or more.

Pyramax Granules for oral suspension are indicated in the treatment of acute, uncomplicated malaria infection caused by Plasmodium falciparum or by Plasmodium vivax in children and infants weighing 5 kg to under 20 kg.

Consideration should be given to official guidance on the appropriate use of antimalarial agents (see section 4.4).

Orphan medicinal product designation dateNot applicable

*This document includes:

Annex I - Summary of product characteristics
Annex IIA - Manufacturer responsible for batch release
Annex IIB - Recommendations to the opinion holder - conditions of use
Annex IIIA - Labelling
Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.

How useful was this page?

Add your rating